Unknown

Dataset Information

0

Kidney involvement in systemic sclerosis: From pathogenesis to treatment.


ABSTRACT: Among all possible systemic sclerosis internal organ complications, kidney involvement is frequently neglected or underestimated, except for the life-threatening scleroderma renal crisis. Fortunately, this severe clinical presentation is nowadays better controlled with available treatments, in particular angiotensin-converting enzyme inhibitors, and this has led to a reduction in its short- and longer-term mortality. Pathogenetic determinants are not well understood and many different other kidney involvements are possible in systemic sclerosis, including proteinuria, albuminuria, reduction of renal filtration, autoantibodies-related glomerulonephritis, and drug-related side effects. Different serological and radiological methods of evaluations are nowadays available, some representing promising diagnostic tool and prognostic outcome measure. Except for angiotensin-converting enzyme inhibitors in scleroderma renal crisis, no other treatment is currently recommended for treatment of kidney involvement in systemic sclerosis. For this reason, further studies are necessary to investigate its prognostic impact, in particular in combination with other systemic sclerosis-related internal organ manifestations. This review summarizes current available literature on kidney involvement in systemic sclerosis.

SUBMITTER: Bruni C 

PROVIDER: S-EPMC8892882 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Kidney involvement in systemic sclerosis: From pathogenesis to treatment.

Bruni Cosimo C   Cuomo Giovanna G   Rossi Francesca W FW   Praino Emanuela E   Bellando-Randone Silvia S  

Journal of scleroderma and related disorders 20180201 1


Among all possible systemic sclerosis internal organ complications, kidney involvement is frequently neglected or underestimated, except for the life-threatening scleroderma renal crisis. Fortunately, this severe clinical presentation is nowadays better controlled with available treatments, in particular angiotensin-converting enzyme inhibitors, and this has led to a reduction in its short- and longer-term mortality. Pathogenetic determinants are not well understood and many different other kidn  ...[more]

Similar Datasets

| S-EPMC7918752 | biostudies-literature
| S-EPMC4459100 | biostudies-literature
| S-EPMC3218751 | biostudies-literature
| S-EPMC5534276 | biostudies-literature
2014-07-25 | E-GEOD-59785 | biostudies-arrayexpress
2014-07-25 | GSE59785 | GEO
| S-EPMC7404317 | biostudies-literature
| S-EPMC6364098 | biostudies-literature
| S-EPMC3826615 | biostudies-other
| S-EPMC4897985 | biostudies-literature